ASH: Takeda pads case for new leukemia use with 5-year survival data

ASH: Takeda pads case for new leukemia use with 5-year survival data

Source: 
Fierce Pharma
snippet: 

About one-third of chronic myeloid leukemia (CML) patients don’t survive past the five-year mark, in part thanks to built-up resistance to treatment options. And that’s a stat Takeda’s trying to change.

The drugmaker Monday unveiled data showing that among patients who had already tried two or more prior tyrosine kinase inhibitors prior to receiving its Iclusig, more than 50% of those who started on a 45 mg daily dose of the drug and scaled down to a 15 mg daily dose were still alive and hadn’t seen their disease worsen after five years.